• QX77 and the Translational Logic of CMA

  2026-08-22

  QX77 offers translational researchers a mechanistically anchored way to study chaperone-mediated autophagy through LAMP2A and Rab11 regulation, while also probing embryonic stem cell self-renewal and differentiation. This article positions the compound within a broader research strategy informed by recent findings on the ETS1–SENP2–HSPA8–FUNDC1 axis in bronchopulmonary dysplasia, emphasizing experimental validation, cross-domain limitations, and responsible pathway interpretation.

• Functional Neutrophils for Next-Gen Immunotherapy

  2026-08-21

  Neutrophil biology is becoming a strategic variable in cancer immunotherapy, particularly as biomimetic mRNA platforms seek to activate tumor-associated neutrophils rather than merely avoid them. This article explains how negative-selection isolation, functional quality control, and source-aware experimental design can strengthen translational studies built around these emerging mechanisms.

• Moxidectin: From Dewormer to Assay Probe

  2026-08-20

  Moxidectin is a macrocyclic lactone anthelmintic with an established antiparasitic role and an emerging function as a polyene antifungal potentiator. This article focuses on the assay design, mechanistic controls, and translational limits needed to evaluate that cross-domain opportunity rigorously.

• Protease Inhibitor Cocktail: EDTA-Free DMSO

  2026-08-20

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolysis during protein extraction and protease-sensitive assays by combining inhibitors with activity against serine, cysteine, and acid proteases, as well as aminopeptidases. It is appropriate for EDTA-sensitive workflows, but DMSO tolerance, cell-line sensitivity, and the need for separate metalloprotease control must be evaluated before routine use.

• Ibuprofen as an Emerging Environmental Contaminant

  2026-08-19

  The 2023 Molecules review reframes ibuprofen as both a widely used COX inhibitor and a persistent emerging contaminant, connecting pharmaceutical consumption with aquatic and soil toxicity. Its central practical contribution is an integrated assessment of environmental entry, cytotoxic and ecological effects, and the prospects and limitations of bacterial biodegradation.

• Camptothecin Workflows for DNA Damage Research

  2026-08-19

  Camptothecin provides a mechanistically focused way to create topoisomerase I-linked DNA damage, making it useful for γH2AX, apoptosis, senescence, autophagy, and cancer-cell response studies. This guide translates its chemistry and signaling profile into practical assay workflows while showing how recent work on adaptive mutagenesis can improve experimental design.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-18

  FITC-Concanavalin A (ConA) Conjugate, SKU K4413, provides direct green-fluorescence labeling of cell-surface and tissue-associated α-D-glucose and α-D-mannose moieties for glycobiology workflows. It is suitable for immunofluorescence staining and flow cytometry carbohydrate analysis, but it should not be treated as a general protein-labeling reagent or used outside the specified storage and stability conditions.

• Baicalin Methyl Ester and LPS-Driven Gut Barrier Injury

  2026-08-18

  A 2024 Biomedicine & Pharmacotherapy study found that baicalin methyl ester reduced LPS-associated inflammation and tight-junction disruption in mice and MODE-K intestinal epithelial cells. The work connects these effects to P65/TNF-α/MLCK/ZO-1 signaling and provides a defined preclinical framework for LPS-induced intestinal barrier damage research.

• Magneto-Piezoelectric Scaffolds for Bone Repair

  2026-08-17

  This ACS Nano study develops a dual-responsive, 3D-printed scaffold that combines biofilm disruption with immune-metabolic stimulation for infectious bone defect repair. Its central advance is the targeting of Icam1+ macrophages, where ultrasound-linked JAK2-STAT3 activation and MAPK-JNK suppression increased oxidative phosphorylation and supported reparative angiogenic and osteogenic responses.

• RNA Pol II Loss Activates Apoptosis Beyond Transcription

  2026-08-17

  Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic response linked to degradation of hypophosphorylated RNA Pol IIA, rather than through passive loss of transcription. Their functional-genomic and chemogenetic analyses define the Pol II degradation-dependent apoptotic response and suggest that apparently diverse anticancer drugs can converge on this pathway.

• Sumatriptan Succinate: Assay Workflows

  2026-08-16

  Build more informative migraine, inflammation, and drug-metabolism experiments with Sumatriptan Succinate, a selective 5-HT1 receptor agonist. This guide connects receptor-focused assays with CYP and MAO profiling, practical controls, and troubleshooting strategies.

• Trelagliptin Succinate: From Glucose to Memory

  2026-08-15

  Trelagliptin succinate is more than a long-acting DPP-4 inhibitor for metabolic studies. This article explains how its glucose-lowering action, inflammatory signaling effects, and cognitive endpoints can be integrated into a rigorous diabetes mellitus research workflow.

• ATF5 Peptide Downregulates CYP2B6 in Glioblastoma

  2026-08-15

  The reference study identifies activating transcription factor 5 (ATF5) as a regulator of CYP2B6 in glioblastoma cells and shows that a TAT-fused dominant-negative ATF5 peptide can reduce CYP2B6 protein levels in LN229 and GBM5 cells. The work connects transcription-factor biology, cell-penetrating peptide delivery, and pharmacogenomic strategies for tailoring drug exposure, while also highlighting the need for validation beyond cultured cell lines.

• QX77 and the Logic of CMA Assay Design

  2026-08-14

  QX77 is a molecular chaperone activator for controlled studies of LAMP2A, Rab11, and chaperone-mediated autophagy. This article develops a mechanism-aware assay strategy that distinguishes CMA modulation from mitophagy and avoids overinterpreting cross-pathway results.

• Transcription Termination Limits WEE1-Induced DNA Damage

  2026-08-14

  The 2026 Nucleic Acids Research study shows that transcription termination protects replicating cells from DNA damage caused by WEE1 inhibition. Its genetic and pharmacological experiments identify transcriptional read-through as a modifiable source of transcription–replication conflicts and support CPSF73 inhibition as a potential combination strategy with adavosertib in prostate cancer models.

450 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page